company background image
CSTL logo

Castle Biosciences NasdaqGM:CSTL Stock Report

Last Price

US$23.74

Market Cap

US$675.8m

7D

-2.0%

1Y

-5.7%

Updated

23 May, 2024

Data

Company Financials +

Castle Biosciences, Inc.

NasdaqGM:CSTL Stock Report

Market Cap: US$675.8m

CSTL Stock Overview

A molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions.

CSTL fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Castle Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Castle Biosciences
Historical stock prices
Current Share PriceUS$23.74
52 Week HighUS$26.70
52 Week LowUS$9.26
Beta0.93
1 Month Change18.35%
3 Month Change-0.52%
1 Year Change-5.72%
3 Year Change-59.99%
5 Year Changen/a
Change since IPO10.93%

Recent News & Updates

Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Apr 30
Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Recent updates

Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Apr 30
Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Jan 27
Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Oct 31
Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Jun 13
Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Aug 14
Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Castle Biosciences Q2 2022 Earnings Preview

Aug 08

Is There Now An Opportunity In Castle Biosciences, Inc. (NASDAQ:CSTL)?

Aug 05
Is There Now An Opportunity In Castle Biosciences, Inc. (NASDAQ:CSTL)?

Estimating The Intrinsic Value Of Castle Biosciences, Inc. (NASDAQ:CSTL)

Jun 06
Estimating The Intrinsic Value Of Castle Biosciences, Inc. (NASDAQ:CSTL)

Shareholder Returns

CSTLUS HealthcareUS Market
7D-2.0%-1.1%-0.9%
1Y-5.7%6.9%25.8%

Return vs Industry: CSTL underperformed the US Healthcare industry which returned 6.9% over the past year.

Return vs Market: CSTL underperformed the US Market which returned 28.2% over the past year.

Price Volatility

Is CSTL's price volatile compared to industry and market?
CSTL volatility
CSTL Average Weekly Movement10.3%
Healthcare Industry Average Movement6.8%
Market Average Movement5.9%
10% most volatile stocks in US Market16.0%
10% least volatile stocks in US Market2.8%

Stable Share Price: CSTL has not had significant price volatility in the past 3 months.

Volatility Over Time: CSTL's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007638Derek Maetzoldcastlebiosciences.com

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett’s esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder.

Castle Biosciences, Inc. Fundamentals Summary

How do Castle Biosciences's earnings and revenue compare to its market cap?
CSTL fundamental statistics
Market capUS$675.82m
Earnings (TTM)-US$30.80m
Revenue (TTM)US$250.73m

2.6x

P/S Ratio

-21.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CSTL income statement (TTM)
RevenueUS$250.73m
Cost of RevenueUS$48.69m
Gross ProfitUS$202.03m
Other ExpensesUS$232.83m
Earnings-US$30.80m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.12
Gross Margin80.58%
Net Profit Margin-12.28%
Debt/Equity Ratio2.5%

How did CSTL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.